Patents

U.S. patent granted for noninvasive cervical cancer detection technology

Published in Medical Letter on the CDC and FDA, January 22nd, 2006

SpectRx, Inc. (SPRX) announced it was granted a patent for a method in which its noninvasive cervical cancer detection technology identifies disease. U.S. Patent 6,975,899 recognizes that the technology measures both biochemical and structural changes in tissue in order to better detect diseases such as cancer.

The patent claims the combined use of at least two spectroscopic methods for measuring biochemical and morphological, or structural, changes that occur with diseases such as cancer. The biochemical spectroscopic methods claimed include fluorescence, time resolved fluorescence and fluorescence anisotropy. The morphological spectroscopic methods include absorption,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-01-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry